Portable device to personalize radiation doses for neuroendocrine tumor treatment
The Personalized Remote Radiation Tracking Portable Organ Dosimetry Devise (PRRT PODD)
A portable device to measure how much radiation your organs get during Lutetium-177 peptide receptor radionuclide therapy for people with neuroendocrine tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11166457 on NIH RePORTER |
What this research studies
The project will build a portable device that uses the gamma signals from your Lutetium-177 treatments combined with SPECT/CT imaging to calculate how much radiation your organs and tumors receive. After each treatment the device and images would estimate doses to organs at risk so your care team can decide whether you can safely have more cycles or need dose changes. Researchers will compare the device's measurements to standard dosimetry methods at clinic sites to validate its accuracy and ease of use. The aim is to make personalized PRRT more available so people can be treated based on their own organ doses instead of a single fixed schedule.
Who could benefit from this research
Good fit: Adults with neuroendocrine tumors who are receiving or planning to receive Lutetium-177 peptide receptor radionuclide therapy would be ideal candidates.
Not a fit: People who are not receiving PRRT, who have tumors not treated with 177Lu agents, or who cannot undergo SPECT/CT imaging are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could let clinicians tailor PRRT so you may get more effective doses when safe and reduce the chance of organ damage.
How similar studies have performed: The NETTER-1 trial established fixed-dose 177Lu-DOTATATE as standard care, and retrospective analyses suggest personalized dosimetry can extend benefits, but prospective device-based personalization is still relatively novel.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Miyaoka, Robert S — University of Washington
- Study coordinator: Miyaoka, Robert S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.